Privo Technologies is a pioneering biopharmaceutical company focused on developing innovative locoregional treatments for cancerous tumors and precancerous lesions, primarily in the oral cavity. The company's flagship product, PRV111, is designed for the treatment of head and neck cancers, with additional formulations in development for other cancer types. Privo Technologies operates in the oncology market, targeting patients who require safer and more effective treatment options. The business model revolves around creating advanced drug delivery systems that stabilize drug compounds and deliver them directly to the tumor site, thereby maximizing therapeutic potency while minimizing systemic toxicity. Revenue is generated through clinical trials, partnerships with institutions like the FDA, NCI, and NIDCR, and nondilutive funding exceeding $11.5 million. Privo Technologies aims to provide better and more accessible treatment options to diverse patient populations globally.

Keywords: locoregional treatment, oral cancer, PRV111, polymer technology, oncology, drug delivery, head and neck cancer, clinical trials, nondilutive funding, targeted therapy.